IL150306A0 - Prostaglandin compositions and methods of treatment for male erectile dysfunction - Google Patents
Prostaglandin compositions and methods of treatment for male erectile dysfunctionInfo
- Publication number
- IL150306A0 IL150306A0 IL15030601A IL15030601A IL150306A0 IL 150306 A0 IL150306 A0 IL 150306A0 IL 15030601 A IL15030601 A IL 15030601A IL 15030601 A IL15030601 A IL 15030601A IL 150306 A0 IL150306 A0 IL 150306A0
- Authority
- IL
- Israel
- Prior art keywords
- composition
- erectile dysfunction
- prostaglandin
- treatment
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 208000010228 Erectile Dysfunction Diseases 0.000 title abstract 2
- 201000001881 impotence Diseases 0.000 title abstract 2
- 150000003180 prostaglandins Chemical class 0.000 title 1
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 2
- 229960000711 alprostadil Drugs 0.000 abstract 2
- 239000007853 buffer solution Substances 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 150000002634 lipophilic molecules Chemical class 0.000 abstract 2
- 239000003961 penetration enhancing agent Substances 0.000 abstract 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 abstract 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 abstract 1
- -1 N,N-disubstituted amino Chemical group 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/480,738 US6323241B1 (en) | 2000-01-10 | 2000-01-10 | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| PCT/US2001/000852 WO2001051053A1 (en) | 2000-01-10 | 2001-01-10 | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL150306A0 true IL150306A0 (en) | 2002-12-01 |
Family
ID=23909154
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15030601A IL150306A0 (en) | 2000-01-10 | 2001-01-10 | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| IL150306A IL150306A (en) | 2000-01-10 | 2002-06-18 | Prostaglandin compounds and methods for treating male erectile dysfunction |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL150306A IL150306A (en) | 2000-01-10 | 2002-06-18 | Prostaglandin compounds and methods for treating male erectile dysfunction |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6323241B1 (de) |
| EP (1) | EP1255552B1 (de) |
| JP (2) | JP2003519657A (de) |
| KR (1) | KR100614361B1 (de) |
| CN (1) | CN1394140A (de) |
| AT (1) | ATE290383T1 (de) |
| AU (1) | AU760576C (de) |
| BE (1) | BE2014C001I2 (de) |
| BR (1) | BR0107478A (de) |
| CA (1) | CA2395217C (de) |
| DE (1) | DE60109274T2 (de) |
| ES (1) | ES2236245T3 (de) |
| HK (1) | HK1047700B (de) |
| HU (1) | HUP0204159A3 (de) |
| IL (2) | IL150306A0 (de) |
| MX (1) | MXPA02006758A (de) |
| PT (1) | PT1255552E (de) |
| TR (1) | TR200201769T2 (de) |
| WO (1) | WO2001051053A1 (de) |
| ZA (1) | ZA200205433B (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1002847B (el) | 1997-05-06 | 1998-01-27 | Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως | |
| US6414028B1 (en) * | 1997-11-05 | 2002-07-02 | Nexmed Holdings, Inc. | Topical compositions containing prostaglandin E1 |
| US6825234B2 (en) | 1998-12-10 | 2004-11-30 | Nexmed (Holdings) , Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| EA008720B1 (ru) * | 1998-12-10 | 2007-06-29 | Нексмед (Холдингс), Инк. | Применение композиции на основе простагландина для лечения расстройства сексуального возбуждения у женщин |
| US20050004226A1 (en) * | 1998-12-10 | 2005-01-06 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US6693135B2 (en) * | 2000-01-10 | 2004-02-17 | Nexmed (Holdings) Incorporated | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| US7105571B2 (en) * | 2000-01-10 | 2006-09-12 | Nexmed Holdings, Inc. | Prostaglandin compositions and methods of treatment for male erectile dysfunction |
| US20040110843A1 (en) * | 2000-01-10 | 2004-06-10 | Nexmed (Holdings), Inc. | Methods of treatment of male erectile dysfunction |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20090035221A1 (en) * | 2002-01-25 | 2009-02-05 | Ramsey Sallis | Methods and Compositions for Treatment of Erectile Dysfunction |
| US20090257956A1 (en) * | 2002-01-25 | 2009-10-15 | Ramsey Sallis | Treatment Method for Treatment of Erectile Dysfunction and Premature Ejaculation |
| DK1474143T3 (da) | 2002-01-25 | 2009-01-26 | Modular Properties Ltd | Fremgangsmåder og sammensætninger til bahandling af mandlig erektil dysfunktion |
| MXPA04007828A (es) * | 2002-02-15 | 2004-10-15 | Nexmed Holdings Inc | Composicion de prostaglandina para eltratamiento de la disfuncion erectil. |
| WO2004022064A1 (en) * | 2002-09-06 | 2004-03-18 | Nexmed (Holdings), Inc. | Methods of treatment of male erectile dysfunction |
| GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
| US6841574B2 (en) * | 2003-01-03 | 2005-01-11 | Nexmed Holdings, Inc. | Topical stabilized prostaglandin E compound dosage forms |
| WO2004084908A1 (en) * | 2003-03-21 | 2004-10-07 | Nexmed (Holdings), Inc. | Prostaglandin compositions for the treatment of erectile dysfunction |
| WO2004084878A1 (en) * | 2003-03-21 | 2004-10-07 | Nexmed (Holdings), Inc. | Compositions and methods for treatment of premature ejaculation |
| CA2519691A1 (en) * | 2003-03-21 | 2004-10-07 | Nexmed (Holdings), Inc. | Angiogenesis promotion by prostaglandin compositions and methods |
| CN1777429A (zh) * | 2003-04-02 | 2006-05-24 | 尼克美制药控股有限公司 | 前列腺素组合物和其治疗血管痉挛的应用 |
| US20050159985A1 (en) * | 2003-11-21 | 2005-07-21 | Bertram Carl T. | System and method of stratifying intervention groups and comparison groups based on disease severity index scores and ranges |
| GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
| EP1784225B1 (de) * | 2004-08-19 | 2016-10-05 | Applied Genetics Incorporated Dermatics | Biomimetikum von evodia rutaecarpa-frucht-extrakt zur linderung von entzündungen |
| GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
| GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
| GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
| US9005183B2 (en) * | 2007-05-16 | 2015-04-14 | Health Knight, Llc | System and method for treating erectile dysfunction |
| EP2646015B1 (de) * | 2010-12-02 | 2020-04-22 | Ferring International Center S.A. | Aktives enantiomer aus dodecyl-2-(n,n-dimethylamino)-propionat |
| MX342511B (es) | 2011-04-07 | 2016-10-03 | Nexmed Holdings Inc | Metodos y composiciones para tratar la enfermedad de raynaud. |
| US10226418B2 (en) | 2014-05-12 | 2019-03-12 | Susie Q, Ltd. | Arginine-containing topical composition |
| BR112017015487A2 (pt) | 2015-01-20 | 2018-01-30 | Xoc Pharmaceuticals Inc | Composto; composição; método de tratamento e/ou prevenção de enxaqueca, als, doença de alzheimer, doença de parkinson, distúrbios extrapirimidais, depressão, náusea, êmese, síndrome das pernas inquietas, insônia, agressão, doença de huntington, doença cardiopulmonar, fibrogênese, hipertensão arterial pulmonar, ansiedade, dependências a drogas, distonia, parassonia ou hiperlactinemia em um indivíduo; métodos de agonização dos receptores d2, 5-ht1d, 5-ht1a e 5-ht2c, em um indivíduo; método de antagonização do receptor d3 em um indivíduo; métodos de agonização seletiva dos receptores 5 -ht1d, e 5-ht2c, método de fornecimento de atividade de antagonista funcional no receptor 5 -ht2b ou no receptor 5-ht7, ou em ambos, em um indivíduo; método de fornecimento de atividade de antagonista funcional nos receptores adrenérgicos em um indivíduo |
| CA2974113A1 (en) | 2015-01-20 | 2016-07-28 | Xoc Pharmaceuticals, Inc. | Isoergoline compounds and uses thereof |
| EP3266458A1 (de) | 2016-07-05 | 2018-01-10 | Fagron B.V. | Verfahren und zusammensetzung und kit zur behandlung von erektiler dysfunktion |
| CA3064274A1 (en) | 2017-06-01 | 2018-12-06 | Xoc Pharmaceuticals, Inc. | Ergoline derivatives for use in medicine |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2818855A (en) | 1954-02-11 | 1958-01-07 | Anthony P Miller | Surgical device |
| BE790840A (fr) | 1971-11-01 | 1973-04-30 | Upjohn Co | Solutions de medicaments instables et leur preparation |
| US4127118B1 (en) | 1977-03-16 | 1995-12-19 | Alvaro Latorre | Method of effecting and enhancing an erection |
| US4254145A (en) | 1978-08-16 | 1981-03-03 | American Cyanamid Company | Topical application of prostaglandin hypotensive agents |
| US4311707A (en) | 1979-02-12 | 1982-01-19 | American Cyanamid Company | Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions |
| US4801587A (en) | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
| US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
| US4980378A (en) | 1988-06-01 | 1990-12-25 | Odontex, Inc. | Biodegradable absorption enhancers |
| SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
| US5242391A (en) | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
| ATE173603T1 (de) | 1990-04-25 | 1998-12-15 | Vivus Inc | Behandlung von erektionversagen |
| US5380760A (en) | 1993-11-19 | 1995-01-10 | Minnesota Mining And Manufacturing Company | Transdermal prostaglandin composition |
| CA2215307A1 (en) | 1995-03-14 | 1996-09-19 | Vivus, Incorporated | Pharmaceutical compositions and kits for preventing erectile dysfunction |
| EP1005336A4 (de) * | 1997-07-09 | 2001-01-17 | Androsolutions Inc | Verbesserte verfahren und zusammensetzungen zur behandlung männlicher erektionsstörungen |
| WO1999021558A2 (en) * | 1997-10-28 | 1999-05-06 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| US6046244A (en) * | 1997-11-05 | 2000-04-04 | Nexmed Holdings, Inc. | Topical compositions for prostaglandin E1 delivery |
| US5942545A (en) | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
| US6486207B2 (en) | 1998-12-10 | 2002-11-26 | Nexmed (Holdings), Inc. | Compositions and methods for amelioration of human female sexual dysfunction |
| US6102849A (en) | 1999-04-03 | 2000-08-15 | Hakac; John R. | Non-surgical penile prosthesis |
-
2000
- 2000-01-10 US US09/480,738 patent/US6323241B1/en not_active Expired - Lifetime
-
2001
- 2001-01-10 CA CA002395217A patent/CA2395217C/en not_active Expired - Lifetime
- 2001-01-10 CN CN01803447A patent/CN1394140A/zh active Pending
- 2001-01-10 BR BR0107478-4A patent/BR0107478A/pt not_active Application Discontinuation
- 2001-01-10 DE DE60109274T patent/DE60109274T2/de not_active Expired - Lifetime
- 2001-01-10 HK HK02109079.3A patent/HK1047700B/en not_active IP Right Cessation
- 2001-01-10 EP EP01942300A patent/EP1255552B1/de not_active Expired - Lifetime
- 2001-01-10 WO PCT/US2001/000852 patent/WO2001051053A1/en not_active Ceased
- 2001-01-10 MX MXPA02006758A patent/MXPA02006758A/es active IP Right Grant
- 2001-01-10 HU HU0204159A patent/HUP0204159A3/hu active IP Right Revival
- 2001-01-10 PT PT01942300T patent/PT1255552E/pt unknown
- 2001-01-10 TR TR2002/01769T patent/TR200201769T2/xx unknown
- 2001-01-10 AT AT01942300T patent/ATE290383T1/de active
- 2001-01-10 JP JP2001551477A patent/JP2003519657A/ja active Pending
- 2001-01-10 IL IL15030601A patent/IL150306A0/xx active IP Right Grant
- 2001-01-10 ES ES01942300T patent/ES2236245T3/es not_active Expired - Lifetime
- 2001-01-10 KR KR1020027008845A patent/KR100614361B1/ko not_active Expired - Lifetime
- 2001-01-10 AU AU29349/01A patent/AU760576C/en not_active Expired
-
2002
- 2002-06-18 IL IL150306A patent/IL150306A/en unknown
- 2002-07-08 ZA ZA200205433A patent/ZA200205433B/xx unknown
-
2007
- 2007-07-18 JP JP2007186380A patent/JP2007302690A/ja active Pending
-
2014
- 2014-01-06 BE BE2014C001C patent/BE2014C001I2/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200205433B (en) | 2003-11-26 |
| AU2934901A (en) | 2001-07-24 |
| AU760576C (en) | 2004-04-08 |
| ATE290383T1 (de) | 2005-03-15 |
| KR20020073498A (ko) | 2002-09-26 |
| HUP0204159A2 (hu) | 2003-04-28 |
| IL150306A (en) | 2007-06-03 |
| WO2001051053A1 (en) | 2001-07-19 |
| BE2014C001I2 (de) | 2020-01-30 |
| PT1255552E (pt) | 2005-06-30 |
| ES2236245T3 (es) | 2005-07-16 |
| JP2007302690A (ja) | 2007-11-22 |
| JP2003519657A (ja) | 2003-06-24 |
| HK1047700A1 (en) | 2003-03-07 |
| DE60109274D1 (de) | 2005-04-14 |
| DE60109274T2 (de) | 2006-02-09 |
| US6323241B1 (en) | 2001-11-27 |
| TR200201769T2 (tr) | 2002-11-21 |
| EP1255552B1 (de) | 2005-03-09 |
| HK1047700B (en) | 2005-05-27 |
| CA2395217A1 (en) | 2001-07-19 |
| MXPA02006758A (es) | 2008-09-12 |
| AU760576B2 (en) | 2003-05-15 |
| CA2395217C (en) | 2004-10-26 |
| HUP0204159A3 (en) | 2005-03-29 |
| BR0107478A (pt) | 2002-09-03 |
| KR100614361B1 (ko) | 2006-08-18 |
| EP1255552A1 (de) | 2002-11-13 |
| CN1394140A (zh) | 2003-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL150306A0 (en) | Prostaglandin compositions and methods of treatment for male erectile dysfunction | |
| IL160404A0 (en) | Prostaglandin compositions and methods of treatment for male erectile dysfunction | |
| ATE273714T1 (de) | Topische zusammensetzungen zur prostaglandin e1 abgabe | |
| TR200202308T2 (tr) | Prostaglandin E1 içeren tropikal bileşimler | |
| MXPA05009816A (es) | Composiciones y metodos para el tratamiento de la eyaculacion precoz. | |
| NO934355D0 (no) | Proteinformulering omfattende veksthormon | |
| DE69933128D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von erektiler dysfunktion | |
| EA199700213A1 (ru) | Крем на водной основе для локального применения, способ его приготовления, способ лечения эректильной дисфункции у мужчин, способ лечения аноргазма у женщин, способ лечения микроваскулярных заболеваний и способ лечения ран или хирургических рассечений | |
| DE69802838D1 (de) | Zusammensetzung und verfahren zur behandlung der erektilen disfunktion des penis | |
| AP2003002742A0 (en) | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids | |
| MXPA02012075A (es) | Composicion para mediar el dolor y aparato y metodo para utilizarla. | |
| ZA923486B (en) | Penetration enhancing substance | |
| PL356968A1 (en) | Solubilized pharmaceutical composition for parenteral administration | |
| ATE226428T1 (de) | Verfahren zur herstellung von pharmazeutischen zusammensetzungen | |
| CA2442479A1 (en) | Topical compositions for prostaglandin e1 delivery | |
| ATE294568T1 (de) | Zusammensetzung zur behandlung von verbrennungen | |
| TH8733A (th) | ตัวปลุกฤทธิ์โปรตีนไคเนสเป็นตัวกระตุ้นการผลิตเมลานิน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |